科研之友
微信
新浪微博
Facebook
分享链接
摘要
Cardiovascular diseases represent the primary cause of death in many countries, including Romania. Prevention and treatment of these diseases require important financial funding covered partially by the state or by the patient. If the general practitioner (GP) or the specialist prescribed generic drugs, in the detriment of innovative drugs, that have a higher cost, the pressure on the public health resources would be notably diminished, as well as the patient contribution. Prescribing generic drugs would be an essential factor to boost the national generic drug industry, with all its social economic implications, but at the pharmacy level, releasing innovative drugs would determine supplementary liquidities very necessary for the current payments of goods and services.
- 出版日期2014
